Comparative Pharmacology
Head-to-head clinical analysis: DECADRON LA versus SERVISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON LA versus SERVISONE.
DECADRON-LA vs SERVISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
SERVISONE is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to glucocorticoid receptors, modulating gene transcription, and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
10-20 mg orally once daily in the morning; higher doses up to 40 mg daily for severe cases.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site.
Terminal elimination half-life is 3-4 hours. Clinically, this supports twice-daily dosing for sustained effect.
Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%).
Renal (70-80% as metabolites, 5-10% unchanged); fecal/biliary (15-20%)
Category C
Category C
Corticosteroid
Corticosteroid